{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T18:26:57Z","timestamp":1776796017421,"version":"3.51.2"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,11,7]],"date-time":"2018-11-07T00:00:00Z","timestamp":1541548800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s12149-018-1312-6","type":"journal-article","created":{"date-parts":[[2018,11,7]],"date-time":"2018-11-07T07:30:24Z","timestamp":1541575824000},"page":"119-127","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Phase I\/IIa PET imaging study with 89zirconium labeled anti-PSMA minibody for urological malignancies"],"prefix":"10.1007","volume":"33","author":[{"given":"Akira","family":"Joraku","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Hatano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuya","family":"Kandori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyoshi","family":"Fukumitsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomonori","family":"Isobe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaro","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muneyuki","family":"Sakata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadashi","family":"Hara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuhiro","family":"Nasu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manabu","family":"Minami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichi","family":"Iizumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Nishiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,11,7]]},"reference":[{"key":"1312_CR1","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.nucmedbio.2009.05.007","volume":"36","author":"JP Holland","year":"2009","unstructured":"Holland JP, Sheh Y, Lewis JS. Standardized methods for the production of high specific-activity zirconium-89. Nucl Med Biol. 2009;36:729\u201339.","journal-title":"Nucl Med Biol"},{"issue":"Suppl 1","key":"1312_CR2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s00259-011-1768-2","volume":"38","author":"M Lubberink","year":"2011","unstructured":"Lubberink M, Herzog H. Quantitative imaging of 124I and 86Y with PET. Eur J Nucl Med Mol Imaging. 2011;38(Suppl 1):10\u20138.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1312_CR3","first-page":"1271","volume":"44","author":"I Verel","year":"2003","unstructured":"Verel I, Visser GWM, Boellaard R, Stigter-van Walsum M, Snow GB, van Dongen GAMS. 89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies. J Nucl Med. 2003;44:1271\u201381.","journal-title":"J Nucl Med"},{"key":"1312_CR4","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1002\/jps.20178","volume":"93","author":"ED Lobo","year":"2004","unstructured":"Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci. 2004;93:2645\u201368.","journal-title":"J Pharm Sci"},{"key":"1312_CR5","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/jcb.10661","volume":"91","author":"A Ghosh","year":"2004","unstructured":"Ghosh A, Heston WDW. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem. 2004;91:528\u201339.","journal-title":"J Cell Biochem"},{"key":"1312_CR6","doi-asserted-by":"publisher","first-page":"e41285","DOI":"10.1371\/journal.pone.0041285","volume":"7","author":"CL Grant","year":"2012","unstructured":"Grant CL, Caromile LA, Durrani K, Rahman MM, Claffey KP, Fong GH, et al. Prostate specific membrane antigen (PSMA) regulates angiogenesis independently of VEGF during ocular neovascularization. PLoS One. 2012;7:e41285.","journal-title":"PLoS One"},{"key":"1312_CR7","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s13277-012-0365-8","volume":"33","author":"T Olafsen","year":"2012","unstructured":"Olafsen T, Sirk SJ, Olma S, Shen CK-F, Wu AM. ImmunoPET using engineered antibody fragments: fluorine-18 labeled diabodies for same-day imaging. Tumor Biol. 2012;33:669\u201377.","journal-title":"Tumor Biol"},{"key":"1312_CR8","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1038\/modpathol.2011.112","volume":"14","author":"MK Samplaski","year":"2011","unstructured":"Samplaski MK, Heston W, Elson P, Magi-Galluzzi C, Hansel DE. Folate hydrolase\u00e3 (prostate-specific membrane [corrected] antigen) 1 expression in bladder cancer subtypes and associated tumor neovasculature. Mod Pathol. 2011;14:1521\u20139.","journal-title":"Mod Pathol"},{"key":"1312_CR9","doi-asserted-by":"publisher","first-page":"3884","DOI":"10.1200\/JCO.2012.42.4887","volume":"30","author":"SM Knowles","year":"2012","unstructured":"Knowles SM, Wu AM. Advances in immuno-positron emission tomography: antibodies for molecular imaging in oncology. J Clin Oncol. 2012;30:3884\u201392.","journal-title":"J Clin Oncol"},{"key":"1312_CR10","doi-asserted-by":"publisher","first-page":"2","DOI":"10.2967\/jnumed.108.056887","volume":"50","author":"AM Wu","year":"2009","unstructured":"Wu AM. Antibodies and antimatter: the resurgence of immuno-PET. J Nucl Med. 2009;50:2\u20135.","journal-title":"J Nucl Med"},{"key":"1312_CR11","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ymeth.2013.09.015","volume":"65","author":"AM Wu","year":"2014","unstructured":"Wu AM. Engineered antibodies for molecular imaging of cancer. Methods. 2014;65:139\u201347.","journal-title":"Methods"},{"key":"1312_CR12","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1097\/PPO.0b013e31817b07ae","volume":"14","author":"AM Wu","year":"2008","unstructured":"Wu AM, Olafsen T. Antibodies for molecular imaging of cancer. Cancer J. 2008;14:191\u20137.","journal-title":"Cancer J"},{"key":"1312_CR13","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.2967\/jnumed.116.176206","volume":"57","author":"N Pandit-Taskar","year":"2016","unstructured":"Pandit-Taskar N, O\u2019Donoghue JA, Ruan S, Lyashchenko SK, Carrasquillo JA, Heller G, et al. First-in-human imaging with 89Zr-Df-IAB2M Anti-PSMA minibody in patients with metastatic prostate cancer: pharmacokinetics, biodistribution, dosimetry, and lesion uptake. J Nucl Med. 2016;57:1858\u201364.","journal-title":"J Nucl Med"},{"key":"1312_CR14","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3389\/fphar.2016.00131","volume":"7","author":"YWS Jauw","year":"2016","unstructured":"Jauw YWS, Menke-van der Houven van Oordt CW, Hoekstra OS, Hendrikse NH, Vugts DJ, Zijlstra JM, et al. Immuno-positron emission tomography with zirconium-89-labeled monoclonal antibodies in oncology: what can we learn from initial clinical trials? Front Pharmacol. 2016;7:131.","journal-title":"Front Pharmacol"},{"key":"1312_CR15","first-page":"1023","volume":"46","author":"MG Stabin","year":"2005","unstructured":"Stabin MG, Sparks RB, Crowe E. OLINDA\/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. Nucl Med. 2005;46:1023\u20137.","journal-title":"Nucl Med"},{"key":"1312_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0146-6453(91)90009-6","volume":"21","author":"1990 Recommendations of the International Commission on Radiological Protection","year":"1991","unstructured":"1990 Recommendations of the International Commission on Radiological Protection (1991) ICRP Publication 60. Ann ICRP 21:1\u2013201.","journal-title":"Ann ICRP"},{"key":"1312_CR17","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1053\/j.semnuclmed.2007.04.001","volume":"37","author":"H Jadvar","year":"2007","unstructured":"Jadvar H, Connolly LP, Fahey FH, Shulkin BL. PET and PET\/CT in pediatric oncology. Semin Nucl Med. 2007;37:316\u201331.","journal-title":"Semin Nucl Med"},{"key":"1312_CR18","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s11060-018-2825-5","volume":"138","author":"M Matsuda","year":"2018","unstructured":"Matsuda M, Ishikawa E, Yamamoto T, Hatano K, Joraku A, Iizumi Y, et al. Potential use of prostate specific membrane antigen (PSMA) for detecting the tumor neovasculature of brain tumors by PET imaging with 89Zr-Df-IAB2M anti-PSMA minibody. J Neuro-Oncol. 2018;138:581\u20139.","journal-title":"J Neuro-Oncol"},{"key":"1312_CR19","doi-asserted-by":"publisher","first-page":"947","DOI":"10.2967\/jnumed.116.185538","volume":"58","author":"F Dietlein","year":"2017","unstructured":"Dietlein F, Kobe C, Neubauer S, Schmidt M, Stockter S, Fischer T, et al. PSA-stratified performance of 18F- and 68 Ga-PSMA PET in patients with biochemical recurrence of prostate cancer. J Nucl Med. 2017;58:947\u201352.","journal-title":"J Nucl Med"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12149-018-1312-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-018-1312-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-018-1312-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,7]],"date-time":"2019-11-07T00:31:32Z","timestamp":1573086692000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12149-018-1312-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,7]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["1312"],"URL":"https:\/\/doi.org\/10.1007\/s12149-018-1312-6","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,7]]},"assertion":[{"value":"4 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"ImaginAb (Los Angeles, CA, USA) covered the manufacturing and shipment costs of <sup>89<\/sup>Zr-Df-IAB2M. Tsukuba University Hospital supported the administration cost of the patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}